Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
The salinosporamides are potent proteasome inhibitors among which the parent marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) is currently in clinical trials for the treatment of various cancers. Methods to generate this class of compounds include fermentation and natural pr...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2010-03-01
|
Series: | Marine Drugs |
Subjects: | |
Online Access: | http://www.mdpi.com/1660-3397/8/4/835/ |
id |
doaj-41e6ca02c2574891baf187d144d8ce11 |
---|---|
record_format |
Article |
spelling |
doaj-41e6ca02c2574891baf187d144d8ce112020-11-24T22:46:50ZengMDPI AGMarine Drugs1660-33972010-03-018483588010.3390/md8040835Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other SalinosporamidesBarbara C. PottsKin S. LamThe salinosporamides are potent proteasome inhibitors among which the parent marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) is currently in clinical trials for the treatment of various cancers. Methods to generate this class of compounds include fermentation and natural products chemistry, precursor-directed biosynthesis, mutasynthesis, semi-synthesis, and total synthesis. The end products range from biochemical tools for probing mechanism of action to clinical trials materials; in turn, the considerable efforts to produce the target molecules have expanded the technologies used to generate them. Here, the full complement of methods is reviewed, reflecting remarkable contributions from scientists of various disciplines over a period of 7 years since the first publication of the structure of 1. http://www.mdpi.com/1660-3397/8/4/835/salinosporamide AmarizomibNPI-0052proteasome inhibitortotal synthesissemi-synthesisnatural products chemistryfermentationmutasynthesisprecursor-directed biosynthesisstructure-activity relationshipsanalogs |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Barbara C. Potts Kin S. Lam |
spellingShingle |
Barbara C. Potts Kin S. Lam Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides Marine Drugs salinosporamide A marizomib NPI-0052 proteasome inhibitor total synthesis semi-synthesis natural products chemistry fermentation mutasynthesis precursor-directed biosynthesis structure-activity relationships analogs |
author_facet |
Barbara C. Potts Kin S. Lam |
author_sort |
Barbara C. Potts |
title |
Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides |
title_short |
Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides |
title_full |
Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides |
title_fullStr |
Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides |
title_full_unstemmed |
Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides |
title_sort |
generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides |
publisher |
MDPI AG |
series |
Marine Drugs |
issn |
1660-3397 |
publishDate |
2010-03-01 |
description |
The salinosporamides are potent proteasome inhibitors among which the parent marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) is currently in clinical trials for the treatment of various cancers. Methods to generate this class of compounds include fermentation and natural products chemistry, precursor-directed biosynthesis, mutasynthesis, semi-synthesis, and total synthesis. The end products range from biochemical tools for probing mechanism of action to clinical trials materials; in turn, the considerable efforts to produce the target molecules have expanded the technologies used to generate them. Here, the full complement of methods is reviewed, reflecting remarkable contributions from scientists of various disciplines over a period of 7 years since the first publication of the structure of 1. |
topic |
salinosporamide A marizomib NPI-0052 proteasome inhibitor total synthesis semi-synthesis natural products chemistry fermentation mutasynthesis precursor-directed biosynthesis structure-activity relationships analogs |
url |
http://www.mdpi.com/1660-3397/8/4/835/ |
work_keys_str_mv |
AT barbaracpotts generatingagenerationofproteasomeinhibitorsfrommicrobialfermentationtototalsynthesisofsalinosporamideamarizomibandothersalinosporamides AT kinslam generatingagenerationofproteasomeinhibitorsfrommicrobialfermentationtototalsynthesisofsalinosporamideamarizomibandothersalinosporamides |
_version_ |
1725683540006273024 |